Pipeline

A robust pipeline to treat the most resistant cancers

Diverse tumors demand a diverse arsenal of therapeutic approaches.

From monoclonal and bispecific antibodies, to antibody drug conjugates, to CAR T-cell therapies, discover what we have in development.

CTLA-4

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

Next Milestone

Worldwide Rights

gotistobart
(ONC-392)

2L IO-resistant NSCLC

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

Enrollment
completion 1H 2025

BioNTech

gotistobart
(ONC-392)*

Advanced solid tumors

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

  ±pembrolizumab*

Enrollment
completion 1H 2024

AI-061, PD-1
coformulation

Solid tumors

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

Ph 1 completion 1H 2024

*In partnership with

MERCK

SIGLEC

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

Next Milestone

Worldwide Rights

AI-071

Immune-related adverse events

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

Ph 2 initiation
2H 2024

OncoC4 Logo

ONC-841

Solid tumors

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

Ph 1 initiation
2H 2024

OncoC4 Logo

CD24

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

Next Milestone

Worldwide Rights

ONC-782

Solid and hematologic
malignancies

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

IND enabling
studies Q1 2024

OncoC4 Logo

ONC-783

Hematologic malignancies

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

IND enabling
studies Q1 2024

OncoC4 Logo

ONC-784

Oncology

Preclinical

IND-enabling

Phase 1

Phase 2

Phase 3

IND enabling
studies Q1 2024

OncoC4 Logo

Clinical trials recruiting now

We are currently recruiting patients for 4 clinical trials in a range of indications.

If you or someone you care about is battling cancer, we welcome you to learn more and get in touch.

PRESERVE-009
An open-label phase 1 study on the safety, pharmacokinetics, and efficacy of AI-061 in advanced solid tumors

Indications: melanoma, non–small cell lung cancer, head and neck squamous cell carcinoma, high-grade serous adenocarcinoma of the ovary, primary peritoneal carcinoma, fallopian tube cancer, endometrial cancer, cervical cancer, renal cell carcinoma, bladder cancer, esophageal cancer, gastric cancer, anal cancer, hepatocellular carcinoma, bile duct cancer

PRESERVE-004
A Phase 2 study that compares two doses of gotistobart in combination with a fixed dose of pembrolizumab

Indications: Platinum-resistant ovarian cancer

PRESERVE-001
A Phase 1 open-label study of gotistobart as a monotherapy and in combination with Pembrolizumab

Indications: Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cance, Ovarian Cance, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction adenocarcinoma, Cervical Cancer, AAdenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma

PRESERVE-006
A Phase 2 study examining the safety and efficacy of gotistobart in combination with lutetium Lu 177 vipivotide tetraxetan

Indications: Metastatic Castration-resistant Prostate Cancer

PRESERVE-003
A Phase 3 study of gotistobart versus docetaxel

Indications: Non-Small Cell Lung Cancers that Progressed on PD-1/PD-l1 Inhibitors

ONC-841-002
Safety, Pharmacokinetics (PK) and Efficacy of ONC-841 in Advanced Solid Tumors NCT06352359

Indications: Advanced or metastatic cancers

Clinical trials recruiting soon

For further inquiries about our clinical trials, don’t hesitate to reach out.

Scroll to Top